Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978471009> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2978471009 endingPage "S457" @default.
- W2978471009 startingPage "S457" @default.
- W2978471009 abstract "Purpose: To examine the efficacy and tolerability of adalimumab (ADA), a fully human, anti-TNF-αα monoclonal antibody, in the closure of perianal fistulae in patients with fistulizing Crohn's disease (CD) and history of intolerance (INT) or lost response (LR) to infliximab (INF). Methods: In the first 4 weeks of this ongoing, 52-week, open-label, multicenter study, ADA was administered sc 160 mg at BL, 80 mg at Week 2, and 40 mg at Week 4 to patients who had discontinued previous INF therapy. The subset of patients either had fistulae only with CDAI < 220, or moderately to severely active (CDAI>220) luminal (mucosal) and fistulizing CD. Patients were assessed for complete or partial (≥50% decrease in the number of draining fistulae compared to BL) fistula closure, Perianal Disease Activity Index (PDAI) score, and adverse events (AE). Results: Of 22 patients with fistulae, all had previously discontinued INF: 23% (n = 5) for LR, 77% (n = 17) for INT. Ten (45%) patients had luminal and fistulizing CD, 12 (55%) had fistulae only. The mean BL PDAI score overall (n = 22) was 10.5 ± 2.8; the mean number of fistulae at BL was 2.5 ± 1.2 in patients with fistulizing CD only and 3.8 ± 5.5 in patients with both luminal and fistulizing CD. Week 4 results are presented (table). Treatment-related AE were mild to moderate in severity and similar to those observed in studies of ADA in patients with rheumatoid arthritis (RA). The most common AE were erythema, nausea/dizziness, weakness, and myalgia. One patient with fistulizing CD dropped out due to non-pruritic erythema. No serious AE were reported.Table: PDAI Scores and Fistula Closure at Week 4 of Adalimumab Treatment.Conclusions: Adalimumab induced complete or partial fistula closure in these patients and was well-tolerated. No new safety concerns were identified compared with ADA-treated RA population." @default.
- W2978471009 created "2019-10-10" @default.
- W2978471009 creator A5010685402 @default.
- W2978471009 creator A5039571121 @default.
- W2978471009 creator A5043698257 @default.
- W2978471009 creator A5050219503 @default.
- W2978471009 creator A5050511366 @default.
- W2978471009 creator A5067681275 @default.
- W2978471009 creator A5067839954 @default.
- W2978471009 date "2006-09-01" @default.
- W2978471009 modified "2023-10-18" @default.
- W2978471009 title "Perianal Fistula Closure with 4 Weeks of Adalimumab Therapy in Patients with Fistulizing Crohnʼs Disease and a History of Intolerance or Loss of Response to Infliximab" @default.
- W2978471009 doi "https://doi.org/10.14309/00000434-200609001-01172" @default.
- W2978471009 hasPublicationYear "2006" @default.
- W2978471009 type Work @default.
- W2978471009 sameAs 2978471009 @default.
- W2978471009 citedByCount "0" @default.
- W2978471009 crossrefType "journal-article" @default.
- W2978471009 hasAuthorship W2978471009A5010685402 @default.
- W2978471009 hasAuthorship W2978471009A5039571121 @default.
- W2978471009 hasAuthorship W2978471009A5043698257 @default.
- W2978471009 hasAuthorship W2978471009A5050219503 @default.
- W2978471009 hasAuthorship W2978471009A5050511366 @default.
- W2978471009 hasAuthorship W2978471009A5067681275 @default.
- W2978471009 hasAuthorship W2978471009A5067839954 @default.
- W2978471009 hasConcept C126322002 @default.
- W2978471009 hasConcept C141071460 @default.
- W2978471009 hasConcept C197934379 @default.
- W2978471009 hasConcept C2776341189 @default.
- W2978471009 hasConcept C2777138892 @default.
- W2978471009 hasConcept C2777575956 @default.
- W2978471009 hasConcept C2778260677 @default.
- W2978471009 hasConcept C2778375690 @default.
- W2978471009 hasConcept C2779121184 @default.
- W2978471009 hasConcept C2779134260 @default.
- W2978471009 hasConcept C2779280984 @default.
- W2978471009 hasConcept C2780132546 @default.
- W2978471009 hasConcept C2780580376 @default.
- W2978471009 hasConcept C71924100 @default.
- W2978471009 hasConcept C90924648 @default.
- W2978471009 hasConceptScore W2978471009C126322002 @default.
- W2978471009 hasConceptScore W2978471009C141071460 @default.
- W2978471009 hasConceptScore W2978471009C197934379 @default.
- W2978471009 hasConceptScore W2978471009C2776341189 @default.
- W2978471009 hasConceptScore W2978471009C2777138892 @default.
- W2978471009 hasConceptScore W2978471009C2777575956 @default.
- W2978471009 hasConceptScore W2978471009C2778260677 @default.
- W2978471009 hasConceptScore W2978471009C2778375690 @default.
- W2978471009 hasConceptScore W2978471009C2779121184 @default.
- W2978471009 hasConceptScore W2978471009C2779134260 @default.
- W2978471009 hasConceptScore W2978471009C2779280984 @default.
- W2978471009 hasConceptScore W2978471009C2780132546 @default.
- W2978471009 hasConceptScore W2978471009C2780580376 @default.
- W2978471009 hasConceptScore W2978471009C71924100 @default.
- W2978471009 hasConceptScore W2978471009C90924648 @default.
- W2978471009 hasLocation W29784710091 @default.
- W2978471009 hasOpenAccess W2978471009 @default.
- W2978471009 hasPrimaryLocation W29784710091 @default.
- W2978471009 hasRelatedWork W1588288904 @default.
- W2978471009 hasRelatedWork W1963997208 @default.
- W2978471009 hasRelatedWork W2000908943 @default.
- W2978471009 hasRelatedWork W2085326056 @default.
- W2978471009 hasRelatedWork W2117102124 @default.
- W2978471009 hasRelatedWork W2423402760 @default.
- W2978471009 hasRelatedWork W2611564874 @default.
- W2978471009 hasRelatedWork W2755604283 @default.
- W2978471009 hasRelatedWork W2999859936 @default.
- W2978471009 hasRelatedWork W4226199241 @default.
- W2978471009 hasVolume "101" @default.
- W2978471009 isParatext "false" @default.
- W2978471009 isRetracted "false" @default.
- W2978471009 magId "2978471009" @default.
- W2978471009 workType "article" @default.